cGMP-Aligned · FDA-Registered U.S. Facility · Third-Party COA on Every LotSupplied for Research Use Only
A BioRegenEx MSC exosome vial beside its Certificate of Analysis
BioRegenEx · Research

Potency Assays for MSC Exosomes: Why Particle Counts Fall Short

← Back to Research Library
Reviewed by BioRegenEx Scientific Editorial Team
Published
Purpose Educational overview for physicians and researchers. Supplied for research use only.

A vial label that reads "10 billion particles" says how much material is present. It does not say whether that material does anything. In biologics development, the attribute that addresses biological activity is potency, and for mesenchymal stromal cell (MSC)-derived exosomes it remains one of the hardest quality questions to answer. This article explains what a potency assay is, why the field has not settled on one, and what research buyers can reasonably ask a supplier today.

Identity, Quantity, and Potency Are Different Questions

Release testing for an extracellular vesicle (EV) preparation typically addresses several separate attributes. Identity asks whether the material is what it claims to be, usually through particle size and marker proteins. Quantity asks how much is present. Purity and safety testing cover co-isolated contaminants, sterility, endotoxin, and mycoplasma. Potency asks something different: does this lot show a defined, measurable biological activity relevant to its intended use?

A lot can pass identity and quantity testing and still vary in activity, because particle counters measure particles, not function. Our overview of how MSC exosomes are characterized covers the identity and safety side; potency is the layer above it.

Why Particle Count and Protein Are Weak Surrogates

The MISEV2023 guidance from the International Society for Extracellular Vesicles is direct about the limits of common measurements. Where a technique cannot distinguish vesicles from co-isolated material, the result should be reported as a particle concentration, not an EV concentration. Total protein as a stand-in for EV quantity is generally not recommended, since soluble proteins that co-purify with vesicles inflate the number. The guidance also asks investigators to report each assay's limit of detection and to show linearity with dilution series.

On markers, MISEV2023 notes that no generic marker identifies all EVs. It recommends reporting at least one protein from each of three categories: membrane-associated proteins such as the tetraspanins CD9, CD63, and CD81; cytosolic proteins such as TSG101 and ALIX; and common contaminants such as apolipoproteins as a purity control. These establish that vesicles are present and reasonably clean. None of them measures activity.

Why a Standard Potency Assay Does Not Yet Exist

A widely cited position paper by Gimona and colleagues in Cytotherapy lays out the core difficulty. A potency assay should ideally reflect the product's mechanism of action. For MSC-derived small EVs, described there as vesicles of roughly 50 to 200 nm that carry much of the paracrine activity of the parent cells, the mechanism is likely complex, differs by disease context, and is still being worked out.

The authors propose a pragmatic route: identify the EV attribute most relevant to the intended biological activity, then quantify that attribute in an assay capable of meeting regulatory expectations for validation under ICH guidelines. This means potency is defined relative to an intended use. An assay built around immune modulation may say little about activity in a tissue-repair model, and a single universal potency number for "MSC exosomes" is not a realistic expectation.

The same paper stresses that EVs are products of living cells, so donor, culture conditions, and process changes can all shift the result. Manufacturing consistency and potency testing are therefore tied together.

The Clinical Consequence: Doses That Cannot Be Compared

The lack of an agreed potency measure shows up directly in the clinical literature. A 2025 registry analysis in Frontiers in Medicine reviewed MSC-EV trials registered from 2014 to 2024 and called dose-response a critical but underappreciated gap, with doses expressed in non-interchangeable units across studies. An earlier scoping review of registered EV trials in Cytotherapy reached a similar conclusion, calling for more standardized product characterization and quantifiable product quality attributes.

Until dose can be expressed in units of activity, two preparations with identical particle counts cannot be assumed to be equivalent. That is a reason for caution in interpreting any published result, and a reason to hold research material constant within a study.

What Research Buyers Can Reasonably Ask

Because there is no compendial potency assay, the useful questions are about transparency and consistency. Ask how particle concentration was measured and on which instrument. Ask which identity markers were tested and whether a contaminant marker was included. Ask whether the supplier runs any functional assay, what it measures, and whether results are tracked lot to lot. Ask what is held constant in the process: cell source, passage range, culture medium, and isolation method.

A supplier that describes a functional assay honestly, including its limits, is giving more useful information than one that offers an unexplained "potency" figure. Lot-specific results belong on the certificate of analysis; see How to Read a Certificate of Analysis (CoA) for MSC Exosomes.

Where BioRegenEx Stands

There are no FDA-approved exosome products, and potency standards for EV preparations are still being developed by the scientific and regulatory community. BioRegenEx supplies MSC-derived exosomes for research use only. Our material is cGMP-manufactured in an FDA-registered U.S. facility and ethically sourced from human umbilical cord (Wharton's Jelly) MSCs, with lot-specific documentation so that researchers can account for the material they use. More background is available on our exosome research page.

References

These statements have not been evaluated by the U.S. Food and Drug Administration. BioRegenEx exosome products are provided for research use only and are not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Any treatment decision is made solely between a patient and a licensed healthcare provider.

Important Information

These statements have not been evaluated by the U.S. Food and Drug Administration. BioRegenEx products are not intended to diagnose, treat, cure, or prevent any disease.

Exosome therapy is an emerging regenerative approach. It is investigational, outcomes vary, and individual results cannot be guaranteed. Patient testimonials reflect individual experiences and are not representative of typical results.

References to regulatory standards — including Section 351(a) of the Public Health Service Act — describe the company’s stated quality and compliance approach and should not be interpreted as FDA approval or endorsement of any product.

This presentation is provided for educational and informational purposes only and does not constitute medical advice. Treatment decisions should always be made in consultation with a qualified, licensed healthcare provider.

Need 2026 pricing or a COA? Tell me where to send it — takes about 20 seconds.
Call 281-785-6877 Mon-Fri 8-5 CT
Licensed providers